In the first five months, China's Chinese medicine exports decreased
2021-10-04 20:23:17
According to the latest statistical data from the China Chamber of Commerce for Import and Export of Medicines and Health Products, from January to May 2012, the export volume of Chinese herbal medicine products decreased by 13.9% year-on-year, and the export price increased by 7.5% year-on-year; at the same time, the structure of Chinese medicine export enterprises was diversified. Foreign-funded enterprises accounted for 37.7% of exports, and private enterprises accounted for 46.4%.
It is worth mentioning that, since 2009, the export volume of plant extracts has declined for the first time, a decrease of 2.7% year-on-year. The analysis of the China Medicare Association mainly focused on the changes in the "Census Catalogue" and the unclear classification of export commodity customs codes, causing export stagnation.
In the export market, the traditional market is still the main market for Chinese medicine exports. Japan, Hong Kong, and the United States are in the top three of the export market, and their exports account for 46.0% of the total value of Chinese medicine exports. Japan and the United States showed strong growth, with an increase of 23.5% and 21.5%, respectively, but Hong Kong’s increase was only 1.6%. In addition, the Korean market has grown rapidly, with an increase of 35.7%.
The China Medicare Association believes that the decline in the export volume of Chinese medicine products stems from many factors. First, the company's internal strength is still weak. For example, a single product, less new product research and development, and lack of international talents, the “going out†strategic plan of the enterprise needs to be consolidated; second, the frequent occurrence of quality and safety events in pharmaceuticals and health care products triggers industry confidence crisis, and exports Thirdly, there are frequent changes in national export supervisory policies and the lack of relevant national standards, which makes it difficult for companies to apply for business qualifications, resulting in the obstruction of export of some products. Fourth, the international market, such as the United States, the European Union and other exporting countries, has increasingly stringent regulatory policies, and the access standards have been continuously improved, which to some extent has also hindered the pace of Chinese medicine exports.
It is worth mentioning that, since 2009, the export volume of plant extracts has declined for the first time, a decrease of 2.7% year-on-year. The analysis of the China Medicare Association mainly focused on the changes in the "Census Catalogue" and the unclear classification of export commodity customs codes, causing export stagnation.
In the export market, the traditional market is still the main market for Chinese medicine exports. Japan, Hong Kong, and the United States are in the top three of the export market, and their exports account for 46.0% of the total value of Chinese medicine exports. Japan and the United States showed strong growth, with an increase of 23.5% and 21.5%, respectively, but Hong Kong’s increase was only 1.6%. In addition, the Korean market has grown rapidly, with an increase of 35.7%.
The China Medicare Association believes that the decline in the export volume of Chinese medicine products stems from many factors. First, the company's internal strength is still weak. For example, a single product, less new product research and development, and lack of international talents, the “going out†strategic plan of the enterprise needs to be consolidated; second, the frequent occurrence of quality and safety events in pharmaceuticals and health care products triggers industry confidence crisis, and exports Thirdly, there are frequent changes in national export supervisory policies and the lack of relevant national standards, which makes it difficult for companies to apply for business qualifications, resulting in the obstruction of export of some products. Fourth, the international market, such as the United States, the European Union and other exporting countries, has increasingly stringent regulatory policies, and the access standards have been continuously improved, which to some extent has also hindered the pace of Chinese medicine exports.
Urethral Catheterization Kits,Suture Change Kits,Skin Preparation Kits,Oral Care Kits
Henan Xianghe Medical Materials Co., Ltd. , https://www.xiangheweicai.com